<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713163</url>
  </required_header>
  <id_info>
    <org_study_id>B2021:008</org_study_id>
    <nct_id>NCT04713163</nct_id>
  </id_info>
  <brief_title>COVID-19 Vaccine Induced Immunity</brief_title>
  <official_title>Prospective Evaluation of COVID-19 Vaccine Induced Immunity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Public Health Agency of Canada (PHAC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cadham Provincial Lab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to address the following three objectives:&#xD;
&#xD;
        1. Longitudinal evaluation of the development of CMI responses in response to SARS-CoV-2&#xD;
           Vaccine: T cells isolated from the blood of COVID-19 vaccine recipients will be&#xD;
           evaluated for their functionality in response to vaccine antigens. The temporal and&#xD;
           functional properties of CMI responses will be correlated with the humoral or antibody&#xD;
           responsiveness. CMI responses will be measured in vaccine recipients prior to&#xD;
           vaccination to determine whether the presence or functionality of pre-existing responses&#xD;
           to common cold coronaviruses (CCCs) or previous SARS-CoV-2 infections affect the&#xD;
           development of CMI responses to the COVID-19 vaccine.&#xD;
&#xD;
        2. Identification of cellular and soluble factors that influence vaccine responsiveness:&#xD;
&#xD;
           While it is known that poor clinical outcomes in COVID-19 patients are strongly&#xD;
           associated with markers of systemic inflammation, the influence these systemic markers&#xD;
           will have on COVID-19 vaccine responsiveness is not clear. Using systems biology&#xD;
           approaches, the investigators will perform comprehensive profiling of cellular immune&#xD;
           subsets, inflammatory signatures to identify determinants influencing the development of&#xD;
           CMI responses to vaccine.&#xD;
&#xD;
        3. Examine variability of immune and viral genes and their relationship to vaccine induced&#xD;
           immune responses: Human leukocyte antigen (HLA), T cell receptor (TCR) and B cell&#xD;
           receptor (BCR) proteins are highly genetically diverse and critical to development of&#xD;
           protective immunity. The investigators will perform HLA sequencing on whole&#xD;
           blood-derived DNA samples and TCR and BCR sequencing on sorted, SARS-CoV2 vaccine&#xD;
           antigen-specific T cells and B cells, respectively, to assess how different sequence&#xD;
           combinations impact the CMI responses to vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Nasal T cell responses</measure>
    <time_frame>Change from Baseline to 12 days post second vaccine dose</time_frame>
    <description>Phenotype of CD4 and CD8+ T cells measured by nasal swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic T cell responses</measure>
    <time_frame>Change from Baseline to 12 days post second vaccine dose</time_frame>
    <description>Cytokine responsiveness to SARS-CoV-2-specific CD4 and CD8+ T cells in blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic and nasal antibody responses</measure>
    <time_frame>Change from Baseline to 12 days post second vaccine dose</time_frame>
    <description>IgA and IgG responses to SARS-CoV-2</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Health care or laboratory-based workers</arm_group_label>
    <description>Healthy individuals about to receive any approved COVID-19 vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Outpatients</arm_group_label>
    <description>Outpatients about to receive any approved COVID-19 vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>covid19 vaccine</intervention_name>
    <description>Vaccine</description>
    <arm_group_label>Health care or laboratory-based workers</arm_group_label>
    <arm_group_label>Outpatients</arm_group_label>
    <other_name>moderna or Pfizer mRNA vaccines, or any other vaccine for Covid19 that becomes approved in Canada</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        healthy volunteers eligible to receive Covid-19 vaccines&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all individuals eligible to receive one of the approved SARS-CoV-2/COVID-19 vaccines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  individuals under 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lyle R Mckinnon, PhD</last_name>
    <phone>2049757708</phone>
    <email>lyle.mckinnon@umanitoba.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blake Ball, PhD</last_name>
    <phone>2047892000</phone>
    <email>tblake.ball@canada.ca</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Manitoba</investigator_affiliation>
    <investigator_full_name>Lyle Mckinnon</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04713163/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

